Loading
Life sciences · Review
Infectious Microbes & Diseases · October 22, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Review.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The widespread use of antiretroviral therapy has substantially improved survival among people living with HIV (PLWH), shifting HIV care from opportunistic infection control toward the prevention of long-term non-communicable comorbidities. Metabolic syndrome (MetS) is a common and clinically useful marker of clustered metabolic abnormalities in this population. In PLWH, MetS may arise from the combined effects of HIV-related chronic inflammation, ART-associated metabolic changes, and altered adipose tissue distribution, including peripheral lipoatrophy, central obesity, and visceral fat accumulation. However, conventional MetS definitions mainly identify metabolic abnormalities and do not capture their severity, target-organ involvement, or broader kidney and cardiovascular implications. The cardiovascular-kidney-metabolic framework proposed by the American Heart Association links metabolic risk, kidney dysfunction, and cardiovascular disease across progressive stages. In this Review, we summarize the diagnostic criteria, epidemiology, and major determinants of MetS in PLWH and reinterpret this evidence within the cardiovascular-kidney-metabolic framework. We discuss how antiretroviral therapy exposure, immune activation and inflammation, virological control, aging, adiposity, and lifestyle factors may shape cardiovascular-kidney-metabolic risk. Applying this framework to chronic HIV care may move practice beyond MetS identification toward longitudinal assessment of metabolic status, kidney involvement, and cardiovascular risk. This approach may support earlier risk detection, individualized monitoring, antiretroviral regimen optimization, lifestyle intervention, and multidisciplinary prevention.